ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Biosero, a Part of BICO Biosciences, Is Awarded a New Patent for Laboratory Automation Scheduling Software

Granted by the United States Patent and Trademark Office, with extensions filed globally, the patent covers an approach that gives laboratories the ability to increase productivity for time and cost efficiencies.

Biosero, Inc., a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, announced the issuance of a key patent underlying its Green Button Go® Scheduler, laboratory automation scheduling software. This patent will accelerate the Bioconvergence Revolution by enabling the implementation of larger, more connected automated scientific solutions while also providing an unprecedented degree of process flexibility that has been missing in lab automation to date.

Biosero’s Green Button Go software allows scientists to automate workflows ranging from a single workstation to operations that span multiple labs. With a number of extensions, hundreds of available drivers, and an intuitive control interface, Green Button Go software is flexible, scalable, and easily customizable for a broad array of laboratory needs.

“At Biosero, we are committed to delivering innovative laboratory automation solutions to help our customers discover novel scientific insights and accelerate the development of new cures for disease,” said Tom Gilman, CEO of Biosero. “The award of this patent recognizes that innovation and also provides validation that even with many software tools on the market, there is room for a truly novel and differentiated approach.”

The patent, titled “Automated Control of Multi-Process Using Robotic Equipment for Complex Workflows,” covers an important capability known as Multipath Scheduler, which provides users with advanced tools for moving samples through the lab, such as the ability to plot several trajectories for different plates that will be run simultaneously. The technology enables the scheduling and execution of complex labware transportation scenarios that are dynamically planned, optimized, and scheduled across different modes of transportation simultaneously — such as multiple robot arms, tracks, conveyors, and autonomous mobile robots.

“Automated lab workflows are becoming increasingly complex, and automation software has to keep up by giving users more flexibility and more sophisticated features to manage their processes,” said David Dambman, Chief Technology Officer at Biosero and an inventor on the patent. “Our Multipath Scheduler tool represents a core capability for any scheduling software platform and ensures the efficient and robust delivery of labware to where it needs to be in an ever-changing and complex laboratory environment.”

About Biosero, Inc.

Biosero, a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Biosero’s Green Button Go® Scheduler software and integration services match laboratory automation to science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Additionally, Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. Biosero is passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs. For more information, please visit www.biosero.com.

About BICO

Founded in 2016, BICO (formerly CELLINK) is enabling the future of life-saving treatments by reducing the organ shortage and accelerating drug development by providing accessible life science solutions that combine biology and technology (bioconvergence). The company focuses on developing, manufacturing, selling, and supporting its life sciences equipment, consumables, and reagents for both manufacturing as well as research purposes. BICO has more than 25,000 products in the field, sales in more than 65 countries, delivers to all top 20 pharmaceutical companies, and have been cited in more than 10,000 scientific publications. BICO is listed on Nasdaq Stockholm under: BICO.

Contacts

Ruth Petersen, Director of Marketing, Biosero

Phone (US): +1 (858) 880-7376

Email: ruthpetersen@biosero.com

Åsa Hillsten, SVP &Head of Investor Relations, BICO Group AB

Phone: +46 70 0 81 81 17

E-mail: ash@bico.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.